Grhta Homepage image

Current Issue

Vol. 12 No. 1 (2025): January-December 2025
Published: 2025-01-15

Point of View

  • Assessment and value of drugs: report of the focus groups from the XXII National Conference on Pharmaceuticals

    Valentina Drago, Tiziana Mele, Francesca Patarnello, Francesca Randon, Cristina Teruzzi, Filippo Drago
    43-48
    DOI: https://doi.org/10.33393/grhta.2025.3469

  • Towards a Green Health Technology Assessment: embedding Life Cycle Assessment for sustainable choices

    Michela Bobini, Eugenio Di Brino, Americo Cicchetti
    29-33
    DOI: https://doi.org/10.33393/grhta.2025.3399

  • What is needed to successfully implement the EU HTA Regulation enabling broad patient access in Europe

    Iga Lipska, Francois Meyer, Pier-Luigi Canonico, Herbert Altmann, Oriol Solà-Morales
    7-8
    DOI: https://doi.org/10.33393/grhta.2025.3354

Original Research Articles

  • Cost-effectiveness analysis of nirmatrelvir/ritonavir in adult patients at high risk of progressing to severe COVID-19

    Carolina Moreno, Andrea Aiello, Roberto Di Virgilio, Valentina Mazzotta, Andrea Antinori
    168-176
    DOI: https://doi.org/10.33393/grhta.2024.3403

  • Micro-costing analysis from Italian Guidelines for the management of sporadic primary hyperparathyroidism

    Ilaria Valentini, Michele Basile, Fabio Vescini, Giorgio Borretta, Iacopo Chiodini, Marco Boniardi, Marina Carotti, Elena Castellano, Cristiana Cipriani, Cristina Eller-Vainicher, Sandro Giannini, Maurizio Iacobone, Antonio Stefano Salcuni, Federica Saponaro, Stefano Spiezia, Annibale Versari, Guido Zavatta, Zuzana Mitrova, Rosella Saulle, Alexia Giovanazzi, Roberto Novizio, Agostino Paoletta, Enrico Papini, Agnese Persichetti, Irene Samperi, Alessandro Scoppola, Pietro Giorgio Calò, Filomena Cetani, Luisella Cianferotti, Sabrina Corbetta, Maria Luisa De Rimini, Alberto Falchetti, Stefano Laureti, Bruno Madeo, Claudio Marcocci, Sandro Mazzaferro, Vittorio Miele, Salvatore Minisola, Andrea Palermo, Jessica Pepe, Alfredo Scillitani, Franco Grimaldi, Renato Cozzi, Roberto Attanasio
    186-193
    DOI: https://doi.org/10.33393/grhta.2025.3531

  • Health technology assessment (HTA) of prostatic urethral lift (PUL) for the treatment of benign prostatic hyperplasia (BPH) in the Italian context

    Agostino Fortunato, Eugenio Di Brino, Michele Basile, Debora Antonini, Filippo Rumi
    177-185
    DOI: https://doi.org/10.33393/grhta.2025.3401

  • Real-World Evidence and Managed Entry Agreements

    Silvia Adami, Cosetta Bianchi, Elisa Crovato, Gianluca Trifirò
    163-167
    DOI: https://doi.org/10.33393/grhta.2025.3563

  • C(nn) and compassionate use: two approaches for early access. Proposals for a better management

    Alberto Bortolami, Irene Marzona, Paolo Stella, Valentina Acciai, Vito Ladisa, Massimo Medaglia
    158-162
    DOI: https://doi.org/10.33393/grhta.2025.3464

  • Cost-analysis from real-world REDS study on dalbavancin in inpatient treatment of acute bacterial skin and skin structure infections

    Matteo Scortichini, Alessandro Ruggieri, Agnese Cattaneo, Patrizia Mascagni, Paolo Sciattella
    151-157
    DOI: https://doi.org/10.33393/grhta.2025.3363

  • Time to market evaluation for new chemical entities in Italy: a critical analysis of the period 2018-2024

    Alessandro Tedesco, Marzia Bonfanti, PhD, Asia Barugolo, Fulvio Luccini, Patrizia Berto
    141-150
    DOI: https://doi.org/10.33393/grhta.2025.3422

  • Healthcare of patients with immunoglobulin A nephropathy through a retrospective observational study of Italian administrative data

    Luigi Biancone, Gaetano La Manna, Letizia Dondi, Leonardo Dondi, Giulia Ronconi, Silvia Calabria, Irene Dell'Anno, Carlo Piccinni, Immacolata Esposito, Alice Addesi, Nello Martini
    130-140
    DOI: https://doi.org/10.33393/grhta.2025.3397

  • Cost-effectiveness of cenobamate as a therapeutic alternative for the treatment of focal epilepsy in adults with inadequate seizure control

    Martina Paoletti, Angela Ragonese, Luca Budassi, Andrea Marcellusi
    118-129
    DOI: https://doi.org/10.33393/grhta.2025.3341

  • Cost-effectiveness of Brentuximab Vedotin plus chemotherapy as frontline treatment of systemic anaplastic large cell lymphoma in Italy

    Andrea Marcellusi, Chiara Bini, Laura Fioravanti, Silvia Ripoli, Paolo Morelli
    106-117
    DOI: https://doi.org/10.33393/grhta.2025.3306

  • Regional tools for the governance of prescribing behaviour and pharmaceutical spending: from literature to concrete experiences and prospects for change

    Giovanna Scroccaro , Luca Piccoli , Giacomo Vitturi, Maria Cristina Carena, Gianfranco Valenzano
    98-105
    DOI: https://doi.org/10.33393/grhta.2025.3324

  • Management and utilization of the Fund for Innovative Medicines: a multistakeholder qualitative survey on regional and local practices

    Andrea Vitagliano, Marzia Bonfanti, Chiara Lucchetti, Andrea Marcellusi
    89-97
    DOI: https://doi.org/10.33393/grhta.2025.3433

  • Assessing the economic burden of Waldenström’s Macroglobulinemia (WM), Marginal Zone Lymphoma (MZL), and Chronic Lymphocytic Leukemia (CLL)

    Matteo Scortichini, Martina Paoletti, Angela Ragonese, Antonio Cuneo, Marco Vignetti, Pier Luigi Zinzani
    80-88
    DOI: https://doi.org/10.33393/grhta.2025.3365

  • Cost per responder of upadacitinib 30 mg and dupilumab 300 mg in patients with moderate-to-severe atopic dermatitis in italy

    Luca Stingeni, Roberto Ravasio, Chiara Palladino, Sara Di Fino, Anna Levi, Gianluca Ronci, Paolo Gisondi
    70-79
    DOI: https://doi.org/10.33393/grhta.2025.3458

  • D.I.Ri.M.O. project: deprescription, inappropriateness evaluation and therapeutic reconciliation in hospital medicine

    Maria Giulia Pollice, Luca Degli Esposti, Cataldo Procacci, Salvatore Lenti, Domenica Ancona, Carmela Nappi, Biagio Iacolare, Anna Maria Tesse, Domenico Leuci, Mara Masullo, Domenico Tricarico
    61-69
    DOI: https://doi.org/10.33393/grhta.2025.3194

  • Optimization in the HIV treatment: economic and organizational impact analysis of Bictegravir/Emtricitabine/Tenofovir Alafenamide

    Lucrezia Ferrario, Barbara Menzaghi, Giuliano Rizzardini, Alessandro Roccia, Elisabetta Garagiola, Daniele Bellavia, Fabrizio Schettini, Emanuela Foglia
    49-60
    DOI: https://doi.org/10.33393/grhta.2025.3292

  • Cost of illness of Heart Valve Diseases (HVDs): A real-world analysis in Italy

    Paolo Sciattella, Matteo Scortichini
    34-42
    DOI: https://doi.org/10.33393/grhta.2025.3243

  • Economic and clinical burden associated with respiratory syncytial virus and impact of universal immunization with nirsevimab in Italy

    Andrea Marcellusi, Chiara Bini, Barbara Muzii, Samira Soudani, Alexia Kieffer, Matthieu Beuvelet, Elena Bozzola, Fabio Midulla, Eugenio Baraldi, Paolo Bonanni, Sara Boccalini, Luigi Orfeo
    16-28
    DOI: https://doi.org/10.33393/grhta.2025.3182

  • Value contribution of leniolisib in the Treatment of Activated PI3Kδ syndrome (APDS) in Spain using Multi-Criteria Decision Analysis (MCDA)

    María Reyes Abad, Carmen Alerany, Luis Ignacio Gonzalez, Olaf Neth, Concepción Payares-Herrera, Carlos Rodríguez-Gallego, Jose Luis Trillo, Kirsten H. Herrmann, Raquel Figueiredo, Alicia Gil
    9-15
    DOI: https://doi.org/10.33393/grhta.2025.3199

Short Communication

View All Issues